Obesity raises death risk in young breast cancer patients

Obesity raises death risk in young breast cancer patients
Some scientific research has suggested that being obese may have a preventive effect against breast cancer in young women, but a study out Wednesday found the opposite.
PHOTO: Obesity raises death risk in young breast cancer patients

Some scientific research has suggested that being obese may have a preventive effect against breast cancer in young women, but a study out Wednesday found the opposite.

British researchers looked at a data set of 80,000 women across 70 clinical trials and found that being obese raised mortality risk by one third in young women with a certain type of tumour.

The higher mortality was seen in women who had not entered menopause and whose tumours were a type known as estrogen-receptor (ER) positive, said the findings, released ahead of a May 31 presentation at the American Society for Clinical Oncology conference in Chicago.

ER-positive tumours are the most common in breast cancer, making up about 75 per cent of cases.

In young women with ER-positive breast cancer, obesity was associated with a 34 per cent higher risk of breast cancer-related death than in postmenopausal women, or women with ER-negative cancers.

In contrast, obesity had little effect on breast cancer outcomes among 40,000 post-menopausal women with ER-positive disease, or among the 20,000 who had ER-negative tumours.

"Obesity substantially increases blood estrogen levels only in post-menopausal women, so we were surprised to find that obesity adversely impacted outcomes only in pre-menopausal women," said Hongchao Pan, a researcher at Oxford University.

"This means we don't understand the main biological mechanism by which obesity affects prognosis."

The study was funded by Cancer Research UK and the British Heart Foundation.

"This study is part of the growing body of evidence showing that patients who are obese generally fare worse with cancer -- in this case, younger women with breast cancer," said Clifford Hudis, president of the American Society for Clinical Oncology.

This website is best viewed using the latest versions of web browsers.